WuXi AppTec(SH:603259) Zhong Guo Ji Jin Bao·2026-01-13 10:27Core Viewpoint - The pharmaceutical sector, particularly companies integrating AI technologies, has shown significant growth, with Ark Health and WuXi AppTec leading the surge in stock prices, reflecting a broader market trend in Hong Kong [1][2]. Group 1: Market Performance - The Hang Seng Index rose by 0.9% to close at 26,848.47 points, with a total market turnover of HKD 315.19 billion, an increase from HKD 306.22 billion in the previous trading day [1]. - Among the constituents of the Hang Seng Index, 53 stocks increased while 33 declined, with WuXi AppTec rising by 8.30% and WuXi Biologics by 5.85% [2]. Group 2: Individual Stock Highlights - WuXi AppTec's stock price reached HKD 120.00, reflecting an increase of 8.30%, with a year-to-date gain of 21.58% [3]. - WuXi Biologics closed at HKD 39.78, up 5.85%, marking a year-to-date increase of 26.53% [3][13]. - Alibaba's stock rose by 3.63% to HKD 159.90, with a significant trading volume of HKD 24.54 billion [3][4]. Group 3: Ark Health's Performance - Ark Health's stock surged by 65.8% to close at HKD 3.93, with a peak increase of 76.37% during the trading session [4][7]. - The company recently partnered with Tencent Health to enhance its "AI + Chronic Disease Management" technology, marking a significant advancement in the sector [7]. Group 4: WuXi AppTec's Financial Outlook - WuXi AppTec announced a positive earnings forecast, projecting a 102.65% year-on-year increase in net profit for 2025, with expected revenue of approximately HKD 454.56 billion, a 15.84% increase [8][10]. - The company anticipates adjusted net profit of about HKD 149.57 billion, reflecting a 41.33% growth [10]. Group 5: WuXi Biologics' Strategic Developments - WuXi Biologics is set to present at the 44th Annual J.P. Morgan Healthcare Conference, highlighting its end-to-end CRDMO platform and a record number of new projects [16][18]. - The company reported a historical high of 209 new projects signed in 2025, with a focus on expanding its commercial pipeline and digital efficiency [18].